respiratori
syncyti
viru
rsv
wide
distribut
pathogen
caus
sever
diseas
children
elderli
immunocompromis
individu
vaccin
develop
drug
discoveri
hamper
inher
instabl
viru
drug
discoveri
effort
limit
success
due
least
part
lack
antivir
assay
robust
enough
highthroughput
screen
instabl
purifi
viru
long
recogn
problem
rsv
research
major
hurdl
produc
virusbas
screen
assay
use
frozen
rsvinfect
cell
sourc
infecti
materi
overcom
problem
viru
instabl
valid
cellbas
highthroughput
screen
assay
screen
inhibitor
rsvinduc
cytopath
effect
assay
valid
compound
identifi
potenti
activ
rsv
long
strain
virusbas
screen
date
compound
screen
sever
month
minim
variabl
cell
viru
control
longterm
assay
stabil
studi
still
progress
introduct
r
espiratori
syncyti
viru
rsv
famili
paramyxovirida
often
associ
bronchiti
pneumonia
among
infant
children
year
age
elderli
compromis
immun
system
cardiac
diseas
pulmonari
diseas
also
risk
sever
lower
respiratori
diseas
rsv
infect
cost
million
annual
due
hospit
indirect
medic
cost
avail
chemotherapeut
agent
limit
ribavirin
prophylact
human
monoclon
antibodi
synagi
medimmun
use
hospit
highrisk
pediatr
patient
viru
instabl
well
document
sinc
earli
day
rsv
research
still
problemat
vaccin
develop
drug
discoveri
today
current
vaccin
prevent
diseas
live
attenu
vaccin
develop
limit
shelf
life
due
viru
instabl
make
product
distribut
vaccin
difficult
vaccin
therapeut
agent
critic
need
rsv
drug
discoveri
hamper
lack
robust
antivir
assay
highthroughput
screen
ht
mason
et
al
use
biochem
assay
identifi
novel
scaffold
small
molecul
screen
inhibit
rsv
viral
rnadepend
rna
polymeras
identifi
broad
class
compound
effect
multipl
target
cellbas
antivir
assay
would
highli
desir
knowledg
report
ht
screen
effort
identif
rsv
inhibitor
use
cytopath
effect
cpe
endpoint
due
part
instabl
viru
inconsist
result
produc
ht
campaign
develop
number
robust
cpebas
antivir
assay
use
ht
campaign
earli
attempt
develop
cpebas
assay
rsv
prove
difficult
develop
optim
cellbas
screen
potenti
rsv
antivir
compound
measur
cpe
induc
rsv
long
strain
infect
cell
use
luminescentbas
viabil
endpoint
ctg
promega
measur
cell
viabil
number
modif
medium
formul
viru
stock
prepar
investig
screen
intern
proprietari
librari
run
viru
instabl
stop
screen
overcom
viru
instabl
issu
methodolog
field
retrovirolog
ht
combin
produc
robust
reproduc
ht
assay
retrovirus
also
found
unstabl
purifi
viru
stock
result
research
field
use
infect
cell
perpetu
viral
infect
cell
cultur
frozen
infect
cell
fic
use
standard
cell
cryopreserv
methodolog
longterm
storag
infecti
materi
cell
remain
infecti
year
store
liquid
nitrogen
use
reestablish
infect
addit
uninfect
cell
cultur
ht
frozen
cell
routin
use
sourc
cell
screen
cell
thaw
dilut
plate
assay
plate
mani
cellbas
assay
help
minim
variabl
often
observ
cellbas
assay
due
passag
number
variabl
two
strategi
combin
creat
robust
reproduc
rsv
assay
ht
use
rsv
fic
sourc
infecti
materi
abbrevi
cpe
cytopath
effect
ctg
celltiterglo
dmso
dimethyl
sulfoxid
ec
effect
concentr
fb
fetal
bovin
serum
fic
frozen
infect
cell
ht
highthroughput
screen
rsv
respiratori
syncyti
viru
tcid
tissu
cultur
infecti
dose
cell
american
type
cultur
collect
maintain
gibco
fetal
bovin
serum
fb
gibco
hifb
unitsml
penicillin
mgml
streptomycin
gibco
flask
cell
split
twice
week
incub
co
rel
humid
passag
medium
trypsinedta
gibco
prewarm
medium
remov
monolay
wash
ml
phosphatebuff
salin
ml
trypsinedta
ad
flask
incub
min
seven
millilit
complet
optimem
ad
ml
cell
suspens
transfer
new
contain
ml
medium
flask
incub
co
rel
humid
fic
stock
prepar
infect
cm
tissu
cultur
flask
confluenc
tissu
cultur
medium
aspir
flask
ml
complet
assay
medium
contain
recent
harvest
hightit
rsv
ad
flask
distribut
evenli
provid
multipl
infect
flask
incub
co
h
incub
ml
complet
assay
medium
ad
flask
flask
return
incub
addit
h
h
total
incub
flask
remov
incub
medium
aspir
discard
cell
wash
two
time
phosphatebuff
salin
trypsin
ml
trypsin
min
cell
harvest
count
viabil
evalu
trypan
blue
exclus
determin
least
viabl
cell
centrifug
remov
trypsin
resuspend
fb
dimethyl
sulfoxid
dmso
concentr
viabl
cellsml
cell
dispens
ml
aliquot
rate
frozen
transfer
freezer
longterm
storag
viabil
also
evalu
thaw
use
calcul
least
similar
evalu
effect
concentr
ec
valu
compound
tissu
cultur
infecti
dose
tcid
valu
infecti
materi
use
strategi
similar
one
use
evalu
doserespons
data
compound
determin
tcid
fic
activ
case
defin
number
rsvposit
well
plot
fic
dilut
log
scale
fic
quantit
dilut
fic
stock
plate
densiti
cellsml
log
dilut
done
uninfect
cell
densiti
one
hundr
ninetytwo
well
half
plate
seed
cell
mixtur
cellswel
dilut
cell
viabil
determin
day
postinfect
use
celltiterglo
ctg
infect
well
show
greater
reduct
signal
score
posit
viru
tcid
determin
plot
number
virusposit
well
versu
dilut
fig
excel
xlfit
formula
use
calcul
dilut
infect
well
occur
tcid
defin
amount
viru
produc
cpe
well
infect
express
log
dilut
assay
medium
assay
medium
use
dulbecco
modifi
eagl
sigma
penicillinstreptomycinglutamin
gibco
ad
final
concentr
vv
ph
adjust
use
naoh
medium
filter
steril
fb
ad
final
concentr
vv
assay
medium
store
dark
compound
dilut
mm
assay
medium
ml
dilut
compound
plu
ml
medium
transfer
assay
plate
cell
viru
control
ml
medium
contain
dmso
dispens
well
compound
handl
done
biomek
fx
p
beckman
coulter
cell
ad
ml
use
wellmat
matrix
final
compound
concentr
mm
dmso
cellswel
control
drug
ribavirin
dilut
assay
medium
contain
dmso
mm
ml
dispens
control
well
final
concentr
mm
dmso
cell
harvest
describ
centrifug
rpm
min
remov
medium
trypsin
suspend
cellsml
use
assay
medium
fic
remov
freezer
thaw
room
temperatur
water
bath
constant
gentl
agit
tube
invert
slowli
time
mix
cell
fic
dilut
give
final
concentr
cellsml
ad
uninfect
cell
predetermin
ratio
determin
empir
produc
ctg
valu
equival
viabil
day
replic
virusbas
assay
result
previous
obtain
tcid
also
determin
lot
fic
way
new
viru
stock
titrat
use
lot
fic
tcid
equival
infect
cellsml
rate
infect
fic
basi
calcul
rsvinfect
cell
dispens
per
well
assay
cell
ad
assay
plate
corn
ml
cellswel
uninfect
cell
ad
cell
control
well
column
repres
inhibit
cell
mix
fic
ad
compound
well
column
viru
control
well
column
repres
inhibit
plate
incub
co
humid
day
syncytia
observ
h
ctg
ad
accord
manufactur
protocol
day
viabil
end
point
read
envis
multilabel
reader
perkin
elmer
use
luminesc
method
integr
time
use
ctg
endpoint
reagent
antivir
assay
evalu
shown
produc
result
consist
neutral
red
uptak
tetrazolium
dye
metabol
data
import
activitybas
idb
analysi
report
compound
well
data
report
inhibit
virusinduc
cpe
percent
cpe
inhibit
luminesc
compound
luminesc
viru
control
median
luminesc
cell
luminesc
viru
control
ec
valu
standard
deviat
calcul
base
inhibit
concentr
substanc
use
paramet
levenburgmarquardt
algorithm
minimum
maximum
paramet
lock
respect
assay
develop
earli
ht
valid
viru
stock
would
retain
infect
vari
length
time
could
long
week
allow
complet
screen
short
week
present
signific
challeng
ht
overt
indic
base
assay
perform
would
allow
predict
pend
crash
end
stabl
period
viru
stock
would
lose
infect
tube
tube
basi
rather
uniform
drop
titer
aliquot
phenomenon
fig
occur
rel
short
period
week
present
major
problem
conduct
ht
screen
campaign
unlik
mani
viralbas
assay
gradual
drop
viru
titer
stock
would
produc
gradual
reduct
assay
window
data
qualiti
behavior
rsv
stock
present
russian
roulett
outcom
screen
run
illustr
figur
doserespons
curv
select
compound
assay
format
assay
plate
prepar
singl
compound
dilut
plate
day
use
uninfect
cell
medium
directli
compar
assay
perform
minim
variabl
singl
replic
point
doserespons
done
compound
assay
format
curv
deriv
ficbas
assay
curv
b
viru
assay
ec
valu
standard
deviat
calcul
base
inhibit
cpe
concentr
n
substanc
use
four
paramet
levenburgmarquardt
algorithm
minimum
maximum
paramet
lock
respect
vial
still
show
infect
vial
highli
variabl
indic
drop
titer
vial
show
minim
virusinduc
cpe
impact
behavior
ht
screen
run
would
mean
either
success
run
control
valu
similar
histor
control
assay
complet
failur
virtual
viru
infect
consid
invest
time
resourc
singl
ht
run
behavior
present
unaccept
financi
risk
work
ficbas
assay
pursu
purpos
develop
ficbas
assay
produc
assay
progress
result
seen
viru
stock
stabl
sourc
infecti
materi
determin
harvest
infect
cell
cryopreserv
cell
harvest
h
postinfect
evalu
tcid
cell
harvest
h
infecti
produc
low
tcid
cell
harvest
h
produc
tcid
cell
harvest
h
reduc
viabil
syncytia
observ
harvest
assay
valid
screen
campaign
vial
fic
prepar
harvest
h
time
point
suffici
stock
screen
million
compound
tabl
show
tcid
valu
fic
week
postfreez
calcul
tcid
valu
consist
time
period
virusbas
assay
attempt
duplic
fic
develop
cpe
suffici
reduc
cell
viabil
day
infecti
dose
fic
requir
produc
progress
determin
empir
low
initi
infecti
dose
fic
allow
multipl
round
viru
replic
infect
cours
assay
would
expect
sourc
initi
infect
would
minim
impact
class
compound
identifi
screen
evalu
compound
use
compar
result
assay
format
ribavirin
standard
refer
compound
avail
demonstr
antivir
activ
rsv
use
posit
control
ht
virusbas
assay
mm
produc
inhibit
viralinduc
cpe
evalu
fic
assay
ribavirin
doserespons
assay
conduct
fic
virusbas
assay
doserespons
data
provid
figur
fic
ec
mm
virusiniti
infect
ec
mm
panel
b
respect
evalu
use
fic
sourc
infecti
materi
compound
run
ficadapt
origin
virusbas
assay
doserespons
format
parallel
batch
control
z
valu
assay
plate
run
duplic
shown
figur
panel
data
ficbas
assay
panel
b
virusbas
assay
comparison
doserespons
plot
select
hit
shown
figur
plot
ec
valu
deriv
two
assay
format
compound
show
activ
either
assay
shown
figur
statist
analysi
duplic
ec
valu
produc
pearson
correl
indic
strong
correl
data
set
result
indic
sourc
infecti
materi
rsv
antivir
assay
either
fic
hightit
infecti
viru
affect
compound
ec
data
produc
sinc
viru
stabil
unpredict
repeat
obstacl
execut
ht
assay
use
fic
adopt
ht
campaign
use
rsvfic
methodolog
screen
compound
molecular
librari
small
molecul
repositori
part
nation
institut
health
molecular
librari
probe
product
center
network
project
severson
articl
prepar
assay
perform
consist
cours
screen
includ
plate
screen
period
addit
plate
screen
doserespons
week
later
use
lot
fic
z
valu
screen
averag
hit
rate
calcul
higher
inhibit
fic
screen
compar
hit
rate
observ
virusbas
screen
absolut
valu
cell
viru
control
vari
slightli
depend
ambient
condit
room
temperatur
sinc
ctg
enzymebas
read
viru
control
consist
viabl
entir
screen
campaign
tcid
valu
fic
also
evalu
week
primari
screen
period
afterward
signific
chang
infect
observ
time
period
fic
methodolog
valid
use
success
ht
campaign
ad
novel
assay
develop
strategi
labil
virus
shown
fic
use
place
infecti
viru
ht
antivir
screen
assay
virus
stabl
influenza
unnecessari
virus
stabl
purifi
stock
strategi
develop
assay
robust
enough
ht
develop
method
use
fic
place
infecti
viru
circumv
viru
instabl
abl
complet
screen
campaign
without
encount
problem
infect
stock
howev
longterm
stabil
studi
need
determin
stabil
limit
fic
applic
studi
current
progress
tcid
valu
determin
period
streamlin
assay
ht
evalu
use
frozen
uninfect
cell
place
cell
cultur
use
frozen
cell
decoupl
cell
cultur
screen
simplifi
logist
run
ht
screen
cost
variabl
associ
cell
passag
cell
densiti
reduc
use
frozen
cell
